Scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) developed a drug molecule for Alzheimer’s treatment more than a year ago. A Delhi-based pharma, Hamsa Biopharma has obtained the intellectual property rights of the path-breaking drug molecule. The company will design and implement drug post-marketing trials along with its parent company in the US, IGC pharma.

The drug molecule, TGR63 works on the pathways that render neurons i.e., brain cells dysfunctional in Alzheimer’s, a condition known to have no permanent cure. Ram Mukunda, CEO of IGC Pharm stated that the drug developer, Prof Govindaraju, and his team reiterated hoe the drug molecule has the potential to prevent disease progression and cure the leading cause of dementia and AS.

He added that AS is caused due to the deposition of amyloid peptides in the brain cells and due to its multifactor progenesis, it has prevented the professionals from finding suitable treatment with good safety and tolerability profile. Meanwhile, JNCASR has already established the toxicity profile of the drug molecule, TGR63 through lab tests and mice models in pre-clinical studies.

Source: ET Healthworld